1. Home
  2. COLL vs PRO Comparison

COLL vs PRO Comparison

Compare COLL & PRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COLL
  • PRO
  • Stock Information
  • Founded
  • COLL 2002
  • PRO 1985
  • Country
  • COLL United States
  • PRO United States
  • Employees
  • COLL 357
  • PRO N/A
  • Industry
  • COLL Biotechnology: Pharmaceutical Preparations
  • PRO EDP Services
  • Sector
  • COLL Health Care
  • PRO Technology
  • Exchange
  • COLL Nasdaq
  • PRO Nasdaq
  • Market Cap
  • COLL 1.1B
  • PRO 1.1B
  • IPO Year
  • COLL 2015
  • PRO 2007
  • Fundamental
  • Price
  • COLL $34.62
  • PRO $23.02
  • Analyst Decision
  • COLL Strong Buy
  • PRO Buy
  • Analyst Count
  • COLL 4
  • PRO 8
  • Target Price
  • COLL $44.25
  • PRO $26.46
  • AVG Volume (30 Days)
  • COLL 319.8K
  • PRO 1.7M
  • Earning Date
  • COLL 11-06-2025
  • PRO 10-27-2025
  • Dividend Yield
  • COLL N/A
  • PRO N/A
  • EPS Growth
  • COLL N/A
  • PRO N/A
  • EPS
  • COLL 1.06
  • PRO N/A
  • Revenue
  • COLL $707,007,000.00
  • PRO $351,682,000.00
  • Revenue This Year
  • COLL $21.29
  • PRO $10.33
  • Revenue Next Year
  • COLL $3.36
  • PRO $10.76
  • P/E Ratio
  • COLL $32.88
  • PRO N/A
  • Revenue Growth
  • COLL 22.61
  • PRO 8.92
  • 52 Week Low
  • COLL $23.23
  • PRO $13.61
  • 52 Week High
  • COLL $39.95
  • PRO $29.84
  • Technical
  • Relative Strength Index (RSI)
  • COLL 49.72
  • PRO 79.47
  • Support Level
  • COLL $34.46
  • PRO $22.99
  • Resistance Level
  • COLL $35.90
  • PRO $23.08
  • Average True Range (ATR)
  • COLL 0.97
  • PRO 0.05
  • MACD
  • COLL 0.19
  • PRO -0.25
  • Stochastic Oscillator
  • COLL 69.18
  • PRO 58.07

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

About PRO PROS Holdings Inc.

Pros Holdings Inc provides software solutions that optimize shopping and selling experiences for both business-to-business and business-to-consumer companies across industry verticals in more than nearly 80 countries. Its PROS Platform is designed to help businesses create, optimize and market available offers and handle orders through both first- and third-party digital channels. The firm generates key revenue form the United States of America, Germany, The rest of Europe, Africa, Asia-Pacific, and Middle East regions.

Share on Social Networks: